CPD event - Fifth NCMD Annual Mood Disorders Meeting

The Fifth annual Northern Centre for Mood Disorders (NCMD) meeting aimed at consultant psychiatrists, associate specialists, senior trainees, nurses, and pharmacists interested in mood disorders was originally scheduled for May and was cancelled because of the coronavirus pandemic. However, a half day on-line CPD meeting did take place on Friday, 18th September. The meeting brought together NCMD research activity and clinical practice to provide clinicians with an update of the CURRENT use and availability of different treatments. The half-day afternoon meeting started by examining the burden and risks associated with mood disorders. The concluding presentation provided an overview of a new international consensus regarding how we should think about managing difficult to treat mood disorders. The focus of the meeting was very much on the ‘coal face’ of how to manage patients, providing high quality CPD of relevance to clinicians.

Links to the presentations:

• 'Managing comorbid alcohol use in people with mood disorders' by Julia Sinclair, University of Southampton
• 'MAOIs: If they are worth it, are they available?' by Dr Alan Currie
• 'Pramipexole: An option for depression?' by Dr Stuart Watson
• 'Esketamine: A new therapeutic option?' by Dr Will Stageman
• 'The physical health burden associated with mood disorders' by Dr Tiago Costa
• ‘TMS: BRIGhTMIND and beyond’ by Charlotte Kirkland:
• "Difficult to treat depression": A novel concept that influences and guides practice by Professor Hamish McAllister-Williams

Brief video updates of ongoing NCMD research studies:

• Introduction to research in NCMD and why this is of benefit to all patients and Trusts
• BRIGHtMIND study
• Psilocybin P-TRD study
• R LINK study
• PAX BD study
• RESTORE-Life study